Shanghai Pharmaceuticals Holding (02607): The sustained-release tablets of sitagliptin and metformin from Changzhou Pharmaceutical Factory have been approved for production.

Shanghai Pharmaceuticals Holding (02607) announced that recently, its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory") received the "Drug Registration Certificate" (certificate number: 2026S00307) issued by the National Medical Products Administration for its Sitagliptin Metformin Extended-release Tablets, which has been approved for production. It is reported that Sitagliptin Metformin Extended-release Tablets are suitable for adult type 2 diabetes patients receiving combined treatment with sitagliptin and metformin extended-release tablets. The drug was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012. In June 2024, Changzhou Pharmaceutical Factory submitted an application for registration and listing of the drug to the National Medical Products Administration, which was accepted. As of the date of this announcement, the company has invested approximately RMB 8.49 million in research and development expenses for this drug. According to relevant national policies, generic drugs approved under new registration categories will receive greater support in areas such as medical insurance payment and procurement by medical institutions. Therefore, the approval of production for Sitagliptin Metformin Extended-release Tablets by Changzhou Pharmaceutical Factory is beneficial for expanding the market share of the drug, enhancing market competitiveness, and accumulating valuable experience for the company's future generic drug applications.